27, 2019bevacizumab-bvzr/zirabevbevacizumab/avastin july 23, 2019rituximab-pvvr/ruxiencerituximab/rituxan july 23, 2019adalimumab-bwwd/hadlimaadalimumab/humira november 4, 2019pegfilgrastim-bmez/ziextenzopegfilgrastim/neulasta november 15, 2019adalimumab-afzb/abriladaadalimumab/humira december 6, 2019infliximab-axxq/avsolainfliximab/remicade june 10, 2020pegfilgrastim-apgf/nyvepriapegfilgrastim/neulasta july 6, 2020adalimumab-fkjp/hulioadalimumab/humira december 17, 2020rituximab-arrx/riabnirituximab/rituxan july 28, 2021insulin glargine-yfgn/semgleeinsulin glargine/lantus september 17, 2021ranibizumab-nuna/byoovizranibizumab/lucentis december 17, 2021insulin glargine-aglr/rezvoglarinsulin glargine/lantus december 17, 2021adalimumab-aqvh/yusimryadalimumab/humira february 25, 2022filgrastim-ayow/releukofilgrastim/neupogen april 13, 2022bevacizumab-maly/alymsysbevacizumab/avastin may 26, 2022pegfilgrastim-pbbk/fylnetrapegfilgrastim/neulasta august 2, 2022ranibizumab-eqrn/cimerliranibizumab/lucentis september 1, 2022pegfilgrastim-fpgk/stimufendpegfilgrastim/neulasta september 27, 2022bevacizumab-adcd/vegzelmabevacizumab/avastin december 13, 2022adalimumab-aacf/idacioadalimumab/humira proposed reforms in the united states, biosimilars have not had the expected impact on prices, leading a 2019 proposal to price regulate instead after an exclusivity period. another proposal requires originators to share the underlying cell lines. in 2019, the proposed biologic patent transparency act would help address evergreening "patent thickets" by requiring that all patents protecting a biosimilar be disclosed. biosimilars have found it difficult to get market share, which led biosimilar developer pfizer to sue johnson & johnson over anticompetitive contracts with pharmacy benefit managers which bundle discounts; these are sometimes called the "rebate wall", and the rebates are generally unavailable to customers. market implications the 2012–2019 patent cliff. period of market exclusivity up to date of patent expiration for the ten top-selling biologics for 2011. *enbrel has been granted approval in 2011 for a patent filed in 1995, extending its patent life further 17 years. the legal requirements of approval pathways, together with the costly manufacturing processes, escalates the developing costs for biosimilars that could be between $75–$250 million per molecule. this market entry barrier affects not only the companies willing to produce them but could also delay availability of inexpensive alternatives for public healthcare institutions that subsidize treatment for their patients. even though the biosimilars market is rising, the price drop for biological drugs at risk of patent expiration will not be as great as for other generic drugs; in fact it has been estimated that the price for biosimilar products will be 65%-85% of their originators. biosimilars are drawing market's attention since there is an upcoming patent cliff, which will put nearly 36% of the $140 billion market for biologic drugs at risk (as of 2011), this considering only the top 10 selling products. the global biosimilars market was us$1.3 billion in 2013, and is expected to reach us$35 billion by 2020, driven by the patent expiration of additional ten blockbuster biologic drugs. companies certain companies (in some cases subsidiaries) tend to operate as generic drug manufacturers, with major ones including teva, viatris, and sandoz and may also extend that focus to biosimilars. sandoz, for example, introduced the first biosimilar in the united states. by value the most important biosimilar business is run by celltrion (south korea). newer companies such as india-based cadila pharmaceuticals, sun pharma, aurobindo pharma, lupin and dr. reddy's laboratories as well as canada-based apotex have taken share in traditional generics, which has led older companies to shift their focus to complex drugs such as biosimilars.